Seborrheic dermatitis is a chronic inflammatory dermatologic condition that usually affects the areas of the body with a large density of sebaceous glands, such as the scalp, face, chest, back, axilla, and groin. Overall, it has been reported to affect about 4% of the population. The cause of seborrheic dermatitis is not completely understood but it is thought to be triggered by the overgrowth of a harmless yeast called Malassezia that lives on the skin, or an overreaction by the skin's immune system to this yeast. The diagnosis is based on the location and appearance of rash or lesion. Skin biopsy may be helpful but is rarely indicated. Seborrhoeic dermatitis is managed with treatment that reduces the level of skin yeast - these include creams and shampoo, which can be used safely on a long-term basis.
DelveInsight's, "Seborrhoeic Dermatitis Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Seborrhoeic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for free Sample Report: https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight
Some of Seborrhoeic Dermatitis Companies are:*
Request for free Sample Report: https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight
Current Seborrhoeic Dermatitis Treatment Scenario and Seborrhoeic Dermatitis Emerging Therapies:*How many companies are developing Seborrhoeic Dermatitis drugs? *How many Seborrhoeic Dermatitis drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Seborrhoeic Dermatitis? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Seborrhoeic Dermatitis therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for Seborrhoeic Dermatitis and their status? *What are the key designations that have been granted to the emerging drugs?
Some of Seborrhoeic Dermatitis Therapies are:*Topical roflumilast foam (ARQ-154) *Omiganan (CLS002) *DBI-002 *PAC-14028 *And Many Others
Request for free Sample Report: https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Seborrhoeic Dermatitis: Overview
Pipeline Therapeutics*Comparative Analysis
Therapeutic Assessment
Seborrhoeic Dermatitis - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Seborrhoeic Dermatitis Collaboration Deals
Late Stage Products (Phase III)
ASF 1057:
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)*Comparative Analysis
ARQ-154:
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
DBI-002: Dermbiont
Drug profiles in the detailed report.....
Inactive Products
Seborrhoeic Dermatitis Key Companies
Seborrhoeic Dermatitis Key Products
Seborrhoeic Dermatitis- Unmet Needs
Seborrhoeic Dermatitis- Market Drivers and Barriers
Seborrhoeic Dermatitis- Future Perspectives and Conclusion
Seborrhoeic Dermatitis Analyst Views
Seborrhoeic Dermatitis Key Companies
Appendix
Request for Deatiled TOC: https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company
Contact Person:
Email: info@delveinsight.com
Phone: +19193216187
Address:
City: Albany
State:
Country:
Website: https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-pipeline-insight
Source: www.abnewswire.com
.
(C) 2021 M2 COMMUNICATIONS, source